Every material Form 8-K Annexon, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Annexon reported a wider second-quarter 2026 net loss of $55.3 million, or $0.28 per share, versus $49.2 million in the year-earlier quarter, and said cash and short-term investments were $209.2 million at June 30, 2026. It also added a Month 24 dual primary endpoint to its Phase 3 ARCHER II trial of vonaprument in geographic atrophy while keeping the Month 15 endpoint on track for Q4 2026, and it entered a credit facility of up to $200 million.
Q2 2026 net loss attributable to common stockholders was $55.3 million ($0.28 per share), versus $51.0 million ($0.34 per share) in Q2 2025 as reported in the statement of operations.
R&D expenses rose to $46.6 million from $44.2 million, and G&A expenses rose to $10.6 million from $7.6 million.
Cash, cash equivalents and short-term investments were $209.2 million at June 30, 2026; the company expects this plus credit facility funds to support operations into 2028.
Up to $200 million credit facility with Oxford Finance LLC, with $50 million drawn at closing; Month 15 ARCHER II results expected Q4 2026, Month 24 completion expected Q3 2027.
On August 10, 2026, Annexon appointed retinal surgeon Mark S. Blumenkranz, M.D., M.S.S., to its board of directors, effective immediately. The appointment followed the resignation of director Muneer Satter, who also left the audit committee and stepped down as chair of the nominating committee, and the filing states his resignation was not due to any disagreement with the company. The filing reports no financial results; for shareholders, the change concerns board composition and director pay terms.
Mark S. Blumenkranz, M.D., M.S.S., joined the board effective August 10, 2026, as a Class II director with a term expiring at the 2028 annual meeting, and was also appointed to the Audit Committee and Science and Technology committee.
Muneer Satter resigned from the board, the Audit Committee, and as chair of the Nominating Committee; the company said he served more than eleven years and joined the board in 2015.
Dr. Blumenkranz receives a $40,000 annual retainer, an annual option grant of 65,000 shares, and a 175,000-share stock option granted in lieu of the standard initial grant.
Annexon reported early results from the first ten U.S. and European patients in its open-label FORWARD study of tanruprubart for Guillain-Barré syndrome (GBS), stating that all treated patients showed rapid, clinically meaningful improvement in strength. The company said it plans to submit a Biologics License Application (BLA) in Q4 2026, and the drug is under review by the European Medicines Agency. The update is clinical and early, without financial results, and its impact on shareholders depends on later data and regulatory outcomes.
First ten U.S. and European patients in the FORWARD study (n=10) were reported
All treated patients showed rapid improvement in muscle strength within four days, per the company
Planned Biologics License Application (BLA) submission is targeted for Q4 2026
Tanruprubart is currently under review by the European Medicines Agency (EMA)
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Annexon, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →